Precise classification of cervical carcinomas combined with somatic mutation profiling contributes to predicting disease outcome

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Spaans, Vivian M ^a   Trietsch, Marjolijn D ^a   Peters, Alexander A W ^a   Osse, Michelle ^a   Haar, Natalja Ter ^a   Fleuren, Gert J ^a   Jordanova, Ekaterina S ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Pathology Leiden University Medical Center ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; CYTOSKELETON PROTEIN; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PYCARD PROTEIN, HUMAN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BRAF GENE; CANCER CLASSIFICATION; CANCER INFILTRATION; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CDKN2A GENE; CONTROLLED STUDY; CTNNB1 GENE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; FGFR2 GENE; FGFR3 GENE; FOXL2 GENE; GENE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONSET AGE; PAPILLOMAVIRUS INFECTION; PIK3CA GENE; PPP2R1A GENE; PTEN GENE; RETROSPECTIVE STUDY; SOMATIC MUTATION; TUMOR INVASION; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; CLASSIFICATION; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; CARCINOMA, SQUAMOUS CELL; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); UTERINE CERVICAL NEOPLASMS;

EID: 84941243525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133670     Document Type: Article

References (55)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22: 2675-86. doi: 10.1093/annonc/mdr015 PMID: 21471563
2. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. Tumours of the uterine cervix. WHO Classification of Tumours of Female Reproductive Organs. Fourth edi. Lyon: IARC; 2014. pp. 169-207.
3. Bulk S, Visser O, Rozendaal L, Verheijen RHM, Meijer CJLM. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer. 2005; 113: 1005-9. doi: 10.1002/ijc.20678 PMID: 15515017
4. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu Y-S, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. Elsevier Inc; 2012; 125: 287-291. doi: 10.1016/j.ygyno.2012.01.012
5. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005; 103: 1258-64. doi: 10. 1002/cncr.20877 PMID: 15693030
6. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet. 2011; 378: 1461-84. doi: 10.1016/S0140-6736(11)61351-2 PMID: 21924486
7. Gien LT, Beauchemin M-C, Thomas G. Adenocarcinoma: A unique cervical cancer. Gynecol Oncol. Elsevier B.V.; 2010; 116: 140-6. doi: 10.1016/j.ygyno.2009.09.040
8. Rose PG. Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm? Gynecol Oncol. Elsevier B.V.; 2012; 125: 285-6. doi: 10.1016/j. ygyno.2012.03.010
9. Lee J-Y, Lee C, Hahn S, Kim MA, Kim HS, Chung HH, et al. Prognosis of adenosquamous carcinoma compared with adenocarcinoma in uterine cervical cancer: A systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2014; 24: 289-94. doi: 10.1097/IGC.0000000000000063 PMID: 24407572
10. Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-50. doi: 10.1038/nrc798 PMID: 12044010
11. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. Journal of Clinical Virology. 2005. doi: 10.1016/j.jcv.2004.12.008
12. Kloth JN, Fleuren GJ, Oosting J, de Menezes RX, Eilers PHC, Kenter GG, et al. Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines. Carcinogenesis. 2005; 26: 1493-502. doi: 10.1093/carcin/bgi110 PMID: 15878915
13. Tornesello ML, Buonaguro L, Buonaguro FM. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review. Gynecol Oncol. Elsevier B.V.; 2013; 128: 442-8. doi: 10.1016/j.ygyno.2012.11.017
14. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, et al. Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013; 119: 3776-83. doi: 10.1002/cncr.28288 PMID: 24037752
15. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014; 506: 371-5. doi: 10.1038/nature12881 PMID: 24390348
16. Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, et al. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One. 2014; 9: E93451. doi: 10.1371/journal.pone.0093451 PMID: 24671188
17. Oosterhuis JW, Coebergh JW, Van Veen E-B. Tumour banks: Well-guarded treasures in the interest of patients. Nat Rev Cancer. 2003; 3: 73-7. doi: 10.1038/nrc973 PMID: 12509769
18. De Jong AE, Van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MGEM, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004; 10: 972-80. doi: 10.1158/1078-0432.CCR-0956-3 PMID: 14871975
19. Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both singlenucleotide polymorphisms and mRNA expression. Clin Chem. 2010; 56: 1845-53. doi: 10.1373/clinchem.2010.151233 PMID: 20947696
20. Van Eijk R, Stevens L, Morreau H, Van Wezel T. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. Exp Mol Pathol. Elsevier Inc.; 2012; 94: 121-125. doi: 10.1016/j.yexmp.2012.06.004
21. Fumagalli D, Gavin PG, Taniyama Y, Kim S-I, Choi H-J, Paik S, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010; 10: 101. doi: 10.1186/1471-2407-10-101 PMID: 20233444
22. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. Nature Publishing Group; 2009; 458: 719-24. doi: 10.1038/nature07943
23. Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, et al. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther. 2012; 11: 888-97. doi: 10.1158/1535-7163.MCT-11-0676 PMID: 22383533
24. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012; 134: 333-43. doi: 10.1007/s10549-012-2035-3 PMID: 22538770
25. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-39. doi: 10.1056/NEJMoa040938 PMID: 15118073
26. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3 PMID: 20619739
27. Nout RA, Bosse T, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/?-catenin and P53 pathway activation. Gynecol Oncol. Elsevier Inc.; 2012; 126: 466-73. doi: 10.1016/j.ygyno.2012. 05.012
28. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009; 4: E7887. doi: 10.1371/journal.pone.0007887 PMID: 19924296
29. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91: 355-8. doi: 10.1038/sj.bjc. 6601894 PMID: 15188009
30. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73: 276-84. doi: 10.1158/0008-5472.CAN-12-1726 PMID: 23066039
31. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30: 777-82. doi: 10.1200/JCO.2011.36.1196 PMID: 22271473
32. Chen Y, Wang B-C, Xiao Y. PI3K: A potential therapeutic target for cancer. J Cell Physiol. 2012; 227: 2818-21. doi: 10.1002/jcp.23038 PMID: 21938729
33. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol. 2011; 6: 103-17. doi: 10.1007/s11523-011-0176-7 PMID: 21547565
34. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501. doi: 10.1038/nrc839 PMID: 12094235
35. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81. doi: 10.1056/NEJMoa066838 PMID: 17538086
36. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56. doi: 10.1016/S0140-6736(08)61039-9 PMID: 18653228
37. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011; 25: 341-7. doi: 10. 1038/leu.2010.226 PMID: 21135857
38. Baselga J, Semiglazov V, Van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-7. doi: 10.1200/JCO.2008.18. 8391 PMID: 19380449
39. De la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, et al. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients. Clin Cancer Res. 2015; 21: 2530-2537. doi: 10.1158/1078-0432.CCR-14-2368 PMID: 25724520
40. McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, Lees-Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. Elsevier Inc.; 2013; 128: 409-14. doi: 10.1016/j.ygyno.2012.12.019
41. Miyake T, Yoshino K, Enomoto T, Takata T, Ugaki H, Kim A, et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 2008; 261: 120-6. doi: 10.1016/j.canlet.2007.11.004 PMID: 18180098
42. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6: E22769. doi: 10.1371/journal.pone.0022769 PMID: 21829508
43. Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin K-L. Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women. Int J Oncol. 2009; 34: 409-16. doi: 10.3892/ijo PMID: 19148475
44. Trietsch MD, Spaans VM, Ter Haar NT, Osse EM, Peters AAW, Gaarenstroom KN, et al. CDKN2A (p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol Oncol. 2014; doi: 10.1016/j.ygyno.2014.07.094
45. Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmo?a U, Bidzi?ski M, Olszewski W, et al. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: Relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol. 2011; 42: 1710-9. doi: 10.1016/j.humpath. 2010.01.030 PMID: 21531001
46. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008; 14: 1351-6. doi: 10.1038/nm.1890 PMID: 19029981
47. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010; 120: 2858-66. doi: 10.1172/JCI37539 PMID: 20664172
48. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, et al. Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic KRAS signalling. Nature. 2013; 497: 638-42. doi: 10. 1038/nature12205 PMID: 23698361
49. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14: 38-47. doi: 10.1016/S1470-2045(12)70489-8 PMID: 23200175
50. Roberts PJ, Stinchcombe TE. KRAS mutation: SHOULD WE test for it, and does it matter? J Clin Oncol. 2013; 31: 1112-21. doi: 10.1200/JCO.2012.43.0454 PMID: 23401440
51. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434: 843-50. doi: 10.1038/nature03319 PMID: 15829953
52. Clevers H, Nusse R. Wnt/?-catenin signaling and disease. Cell. 2012; 149: 1192-205. doi: 10.1016/j. cell.2012.05.012 PMID: 22682243
53. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, et al. Mutations of the beta-and gammacatenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001; 85: 64-8. doi: 10.1054/bjoc.2001.1863 PMID: 11437403
54. Shinohara a, Yokoyama Y, Wan X, Takahashi Y, Mori Y, Takami T, et al. Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol. 2001; 82: 450-5. doi: 10.1006/gyno.2001.6298 PMID: 11520139
55. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des. 2013; 19: 634-64. doi: 10.2174/138161213804581837 PMID: 23016862